PerkinElmer Enters Pattern Biomarker Screening with NCI-FDA Ovarian Study | GenomeWeb

PerkinElmer has launched a new biomarker initiative that may lead the company down the path to diagnostics and clinical development, Mary Lopez, business leader for analytical proteomics at PerkinElmer, told ProteoMonitor this week.

“PerkinElmer is a tools company, but we are moving into the area of platforms and solutions,” Lopez said. “We are developing a platform for biomarker screening, and initially it will be a research platform. Whether we go into the clinical area is still something that is under discussion, but is not off the table.”

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.